Anlotinib combined with mXELIRI as second-line treatment in advanced colorectal cancer pretreated with bevacizumab plus standard chemotherapy: A single-arm, phase IB/II study

被引：0
|
作者：
Qu, Xin
Chen, Xian
Li, Yong
Liu, Li-rong
Qu, Yan-chun
Hou, Fang-fang
Li, Wen-zhu
Liu, Yi-hong
Zhu, Yan-juan
Zhang, Haibo
机构：
[1] Guangdong Prov Hosp Chinese Med, Dept Oncol, Guangzhou, Peoples R China
[2] Guangdong Prov Hosp Chinese Med, Guangzhou, Peoples R China
[3] Guangdong Prov Hosp Chinese Med, Guangzhou, Guangdong, Peoples R China
[4] Guangdong Prov Hosp Tradit Chinese Med, Guangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 04期
关键词：
D O I：
10.1200/JCO.2022.40.4_suppl.TPS220
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS220
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Irinotecan plus raltitrexed as second-line treatment in locally advanced or metastatic colorectal cancer patients: a prospective open-label, single-arm, multi-center, phase II study
    Cheng, Yu
    Teng, Zan
    Zhang, Yanqiao
    Jin, Bo
    Zheng, Zhendong
    Man, Li
    Wang, Zhenghua
    Teng, Yuee
    Yu, Ping
    Shi, Jing
    Luo, Ying
    Wang, Ying
    Zhang, Jingdong
    Zhang, Huijuan
    Liu, Jiwei
    Chen, Hao
    Xiao, Jiawen
    Zhao, Lei
    Zhang, Lingyun
    Jiang, Yu
    Chen, Ying
    Zhang, Jian
    Wang, Chang
    Liu, Sa
    Qu, Jinglei
    Qu, Xiujuan
    Liu, Yunpeng
    BMC CANCER, 2024, 24 (01)
  • [22] Efficacy and safety of camrelizumab combined with chemotherapy in the first-line treatment of advanced gastric cancer: a single-arm, phase II study
    Liu, Wenlou
    Wang, Hongmei
    Zhao, Yang
    Ge, Yan
    Tang, Juangjuang
    Cao, Menghan
    Matsas, Silvio
    Breadner, Daniel Adam
    Qin, Xiaobing
    Han, Zhengxiang
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 15 (04)
  • [23] Gemcitabine plus nab-paclitaxel for second-line therapy of pancreatic cancer: A phase II, single-arm, multicenter study
    Huh, Gunn
    Choi, Jin Ho
    Lee, Sang Hyub
    Chun, Jung Won
    Cho, In Rae
    Paik, Woo Hyun
    Ryu, Ji Kon
    Kim, Yong-Tae
    Lee, Hee Seung
    Bang, Seungmin
    ANNALS OF ONCOLOGY, 2021, 32 : S287 - S287
  • [24] A prospective, single-arm, single-center, exploratory clinical study of anlotinib combined with irinotecan in second-line and above treatment of HER-2-negative advanced breast cancer
    Zhang, Y.
    Xu, W.
    Zhao, Y.
    Guo, X.
    Hong, T.
    Yan, Y.
    Wu, X.
    ANNALS OF ONCOLOGY, 2023, 34 : S370 - S370
  • [25] Efficacy and safety of second-line therapy with apatinib combined with chemotherapy as second-line therapy in advanced gastric cancer: a single-arm, open-label, prospective, multicenter study
    Zhang, Yan
    Xu, Junying
    Wang, Qiong
    Ling, Guohong
    Mao, Yong
    Cai, Maohuai
    Yang, Yang
    Mei, Jingfeng
    Han, Zhengxiang
    Feng, Jifeng
    Wu, Yuan
    Shi, Lin
    Wen, Shaodi
    Shen, Bo
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (11)
  • [26] A prospective, single-arm, single-center, exploratory clinical study of anlotinib combined with irinotecan in second-line and above treatment of HER-2-negative advanced breast cancer
    Zhang, Ying
    Xu, Wenhuan
    Zhao, Yutian
    Guo, Xuedan
    Hong, Tingting
    Yan, Yidan
    Wu, Xiaohong
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [27] A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
    Chen, Tom Wei-Wu
    Hsu, Chia-Lang
    Hong, Ruey-Long
    Lee, Jen-Chieh
    Chang, Koping
    Yu, Chih-Wei
    Chen, San-Chi
    Guo, Jhe-Cyuan
    Chen, Mei-Lu
    Hsu, Meng-Chi
    Kung, Ting-Fang
    Cheng, Ann-Lii
    Yen, Chueh-Chuan
    CLINICAL CANCER RESEARCH, 2022, 28 (23) : 5058 - 5065
  • [28] Clinical study on the second-line treatment of advanced esophageal squamous cell carcinoma with camrelizumab combined with apatinib and irinotecan: A single-arm, multicenter, phase II study
    He, Yifu
    Li, Chenghui
    Zhang, Fenglin
    Hu, Bing
    Sun, Yubei
    Xia, Xiaoyang
    Zhang, Yanshun
    Wang, Gang
    Xu, Tengyun
    Duan, Aixiong
    Wu, Shusheng
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [29] Liposomal irinotecan+5-fluorouracil plus leucovorin plus bevacizumab as second-line therapy in metastatic colorectal cancer (IRIS): A multi-center, single-arm, prospective, phase II study.
    Hu, Xuhua
    Jiang, Bo
    Hongxia, Lu
    Yu, Bin
    Yi, Bo
    Wang, Yudong
    Zhu, Lingjun
    Li, Shengmian
    Li, Baokun
    Kong, Dalu
    Wang, Zhiwu
    Niu, Wenbo
    Ma, Hongqing
    Wang, Shanchuan
    Chen, Yanglin
    Lin, Chao
    Yang, Rong
    Zhu, Weiyou
    Liu, Jia
    Wang, Guiying
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 195 - 195
  • [30] Phase II study of anlotinib plus sintlimab as second-line treatment for patients with advanced biliary tract cancers.
    Zong Hong
    Zhong Qian
    Zhao Ruihua
    Jin Shuiling
    Zhou Chuang
    Zhang Xiaojian
    Shi Jianxiang
    Qiao Shishi
    Han Jinming
    Jiang Miao
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
12345